We use cookies, just to track visits to our website, we store no personal details.
Learn More
Accept
Essential Medicines & Vaccines
Admin Home
User Management
My Profile
Regional Users
Countrywide Users
Setup
Organisations
Locations
Manufacturers
Health Facilities
Therapeutic Areas
Medicine Class
Generic Names
Dosage Strength
Dosage Form
Package Size
Funding Source
Regional Dashboards
Health Facilities
Registered Premises
Local Manufacturers
Registered Products
Pharmacovigilance
Good Manufacturing Practices
Quality Control Labs
Regional Data
Registered Premises
Local Manufacturers
Registered Products
Good Manufacturing Practices
Quality Control Labs
Product Stocks
Country Profile
Stock Summary
Stock Status
Stock Pipeline
Inventory Control
Stockout Trend
Shipment Reports
Content Manager
News
Upcoming Event
Alerts
Photo Gallery
Video Gallery
Notifications
Document Manager
Guidelines & Manuals
SOPs & Templates
Expression of Interests
Publication
Library
Feedbacks
Profile
Change Password
Messages
Logout
Lang
English
French
Portuguese
Back to List
Edit
DrugLens ISSUE 8 | August 2020
Author:
Ghana FDA
Category:
Country
Language:
English
Description
DrugLens, a biannual publication by the National Pharmacovigilance Centre of the Food and Drugs Authority (FDA). This newsletter gives a summary of the ADR reports received , drug safety issues of current interest, pharmacovigilance awareness activities and safety monitoring activities by the National Pharmacovigilance Centre. DrugLens is also one of the FDA's commitment to building a world class regulatory authority by communicating timely and accurate safety information and other related activities to stakeholders.
Abstract
DrugLens provides pertinent information regarding new and emerging drug safety issues in Ghana. This information will be used by health care professionals to assist in making the best decisions regarding the use of medicines and to promote the reporting of adverse drug reactions (ADRs). ADR reports received from healthcare professionals helps the FDA in taking appropriate regulatory decisions regarding marketed products ensures that patients derive the maximum benefit from pharmacotherapy.
Download PDF
